# CJC-1295 Side Effects and Safety in the Research Literature | Safe CJC-1295

> CJC-1295 side effects, read from the record: GH-driven fluid retention, the IGF-1 and cancer-risk question, FDA-cited immunogenicity, and the discontinued ConjuChem program — cited.

What is documented, what is theoretical, and what is simply absent — the honest safety reading of an unapproved GHRH analog, with the gaps left marked.

## Reading CJC-1295 side effects honestly

Any reading of CJC-1295 side effects has to start with the gap: there is no long-term human safety trial of the compound. The human record is limited to short early-phase pharmacokinetic studies [1][3] and a discontinued Phase 2 program [7]. So the safety profile is assembled from three sources — what the GH/IGF-1 mechanism predicts, what GH-axis stimulation is known to do in general, and what regulators have flagged — rather than from a dedicated safety dataset.

That does not make the concerns speculative noise. Each one ties to a documented mechanism or a documented epidemiologic association. What it means is that the magnitude and frequency of these effects specifically from CJC-1295 in humans over time are unmeasured. The honest statement is precise on both halves: the mechanisms of concern are real, and the human safety data that would quantify them do not exist.

## Fluid retention and the GH/IGF-1 mechanism

The most predictable effect of GH-axis stimulation is fluid retention. Growth hormone increases extracellular fluid volume by stimulating renal sodium reabsorption in the distal nephron [9]. Because CJC-1295 raises GH and keeps it elevated for days [1], the same sodium-retention mechanism applies, and edema is a documented effect class of GH-raising interventions [9]. GH-axis stimulation also affects substrate metabolism and nitrogen balance [6], and can influence insulin sensitivity — effects that follow from raising growth hormone, whatever the means of raising it.

These are mechanism-derived expectations, well-grounded in GH physiology. What is not available is a controlled measurement of how often, and how severely, they occur with CJC-1295 specifically in humans over a sustained course.

## The IGF-1 and cancer-risk question

The most-cited safety concern is the IGF-1 and cancer-risk question. CJC-1295 raises IGF-1, and sustains it — after multiple doses, IGF-1 stayed above baseline for up to 28 days in healthy adults [1]. A large collaborative meta-analysis associated higher circulating IGF-1 with a modestly increased risk of certain cancers [8], and that epidemiology is the basis for caution about sustained IGF-1 elevation from any GH-axis stimulation.

The relationship is an association in population data, not a demonstrated effect of CJC-1295. The meta-analysis describes risk across naturally varying IGF-1 levels; it does not measure cancer outcomes in CJC-1295 users, because no such study exists. But the logic chain — CJC-1295 sustains elevated IGF-1, and sustained elevated IGF-1 is epidemiologically linked to higher risk of some cancers — is why this is the open question the literature returns to most often.

## Why does the FDA cite immunogenicity as a concern for CJC-1295?

Immunogenicity means the potential of a substance to provoke anti-drug antibodies. FDA briefing materials for the 2024 Pharmacy Compounding Advisory Committee listed immunogenicity among the safety concerns for GH secretagogues including CJC-1295 [8]. Synthetic peptides can be recognized as foreign by the immune system, and an analog that lacks the characterization an approved drug would have — purity, impurity profile, long-term immune data — carries that uncertainty into every batch.

At that 2024 committee, CJC-1295 was reviewed and not recommended for the 503A compounding bulks list [8]. The immunogenicity flag is one reason a peptide can clear a pharmacokinetic study yet still not meet the bar for compounding eligibility: short PK data say nothing about the antibody response over a sustained course.

## The discontinued ConjuChem program

CJC-1295 reached human trials under its original developer, ConjuChem, which ran a Phase 2 study of the DAC form in HIV-associated visceral obesity (registry NCT00267527) [7]. The program was discontinued and the long-acting DAC analog did not advance to approval [7]. A patient death during the development era is frequently cited in connection with the halted program, though a causal link to CJC-1295 was not established in the public record [7].

The discontinuation is itself part of the safety reading. The compound that the strongest community claims rest on is the one whose own commercial development was stopped before it produced the efficacy and long-term safety evidence that an approved drug requires. That is the most concrete reason the long-term human safety question remains open: the program that would have answered it ended.

---

A civic-register dossier on the CJC-1295 record — what the literature establishes marked on the record, the safety gaps left openly blank, and the unapproved status posted plainly; no clinic behind the register and nothing here prescribed or sold.